2023

ISPOR announced the appointment of Nancy J. Devlin, PhD, University of Melbourne, Australia as an editor-in-chief for Value in Health.

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that Mitch Higashi, PhD has joined the Society’s leadership team as Associate Chief Science Officer.

Value in Health announced the publication of 2 new commentaries by leading experts in health economics and outcomes research, both of which raise important questions as the Centers for Medicare & Medicaid Services move forward to implement the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Value in Health announced the publication of a study showing that United States Medicare could save up to an additional $5-$10 billion dollars annually across 10 drugs if it negotiated prices using a therapeutic reference pricing approach rather than using the statutory ceiling price alone.

Value in Health, the official journal of ISPOR, announced the publication of the results of a systematic literature review showing that there is sparce evidence in the health research literature to link health technology assessment processes and outcomes with device purchasing decisions

ISPOR announced the recipients of its 2023 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards.

ISPOR announced the plenary sessions and speakers for ISPOR Europe 2023. The conference is scheduled for 12-15 November in Copenhagen, Denmark with the theme, “Health Economics and Outcomes Research at the Nexus of Policy and Science.”

Value in Health, the official journal of ISPOR, announced the publication of a report that identifies expensive Medicare Part B drugs with low added therapeutic benefit and models a reimbursement policy for them based on domestic reference pricing.

ISPOR announced that Laura Pizzi, PharmD, MPH will be assuming the role of Chief Science Officer at the Society. ISPOR’s previous Chief Science Officer, Richard J. Willke, PhD, will be retiring.

Value in Health published a new ISPOR Report that provides an overview of gaps and challenges in the value assessment of biosimilars and identifying potential approaches to address them. The report was published in the August 2023 issue of Value in Health.